​

TG Therapeutics (TGTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TGTX Stock Forecast

TG Therapeutics (TGTX) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $49.50, with a high of $60.00 and a low of $39.00. This represents a 83.74% increase from the last price of $26.94.

$10 $20 $30 $40 $50 $60 High: $60 Avg: $49.5 Low: $39 Last Closed Price: $26.94

TGTX Stock Rating

TG Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (84.62%), 1 Hold (7.69%), 1 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 1 11 0 Strong Sell Sell Hold Buy Strong Buy

TGTX Price Target Upside V Benchmarks

TypeNameUpside
StockTG Therapeutics83.74%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$39.00$49.50
Last Closing Price$26.94$26.94$26.94
Upside/Downside-44.77%83.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26161-19
Feb, 26161-19
Jan, 26161-19
Dec, 25161-19
Nov, 25251-19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 15, 2026Goldman Sachs$39.00$29.5432.02%44.77%
Oct 06, 2025Emily BodnarH.C. Wainwright$60.00$36.7163.44%122.72%
Nov 05, 2024Edward WhiteH.C. Wainwright$27.50$12.93112.68%2.08%
Aug 06, 2024Corinne JenkinsGoldman Sachs$20.00$20.58-2.82%-25.76%
May 03, 2024Edward WhiteH.C. Wainwright$24.50$8.21198.42%-9.06%
Feb 07, 2023Cantor Fitzgerald$24.00$18.4829.87%-10.91%
Dec 30, 2022Evercore ISI$16.00$11.8335.25%-40.61%
Dec 29, 2022Edward WhiteH.C. Wainwright$12.00$4.23183.69%-55.46%
Apr 19, 2022Goldman Sachs$5.00$7.26-31.13%-81.44%
Apr 18, 2022Mayank MamtaniTelsey Advisory$11.50$3.46232.37%-57.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 15, 2026Goldman SachsNeutralNeutralhold
Jan 14, 2026Cantor FitzgeraldOverweightOverweighthold
Sep 17, 2025B. RileyBuyBuyhold
Oct 29, 2024H.C. WainwrightBuyBuyhold
Oct 29, 2024Cowen & Co.Buyinitialise
Oct 24, 2024B. RileyBuyBuyhold
Sep 18, 2024H.C. WainwrightBuyBuyhold
Aug 06, 2024Goldman SachsNeutralNeutralhold
May 03, 2024H.C. WainwrightBuyBuyhold
Aug 02, 2023Goldman SachsSellNeutralupgrade

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.63$-1.46$0.09$0.16$3.10---
Avg Forecast$-2.56$-1.34$-0.01$0.11$1.00$1.78$2.86$3.71
High Forecast$-2.01$-1.17-$0.16$1.52$2.24$3.33$3.85
Low Forecast$-3.06$-1.55$-0.02$0.05$0.44$0.97$2.53$3.42
Surprise %2.73%8.96%-1000.00%45.45%210.00%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.69M$2.79M$233.66M$329.00M$616.29M---
Avg Forecast$7.01M$4.27M$231.08M$320.87M$534.67M$748.29M$997.20M$1.26B
High Forecast$8.07M$4.78M$231.20M$326.08M$535.99M$748.31M$1.00B$1.29B
Low Forecast$5.85M$3.84M$230.90M$315.78M$533.35M$748.27M$991.12M$1.18B
Surprise %-4.59%-34.74%1.12%2.54%15.27%---

Net Income Forecast

$-500M $-200M $100M $400M $700M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-348.10M$-223.81M$12.67M$23.38M$447.18M---
Avg Forecast$-380.37M$-199.66M$-1.70M$15.43M$168.38M$273.41M$448.46M$550.22M
High Forecast$-298.35M$-173.92M$-424.17K$23.60M$226.28M$332.62M$493.91M$571.30M
Low Forecast$-454.86M$-230.73M$-2.97M$7.26M$65.27M$144.20M$375.07M$507.85M
Surprise %-8.48%12.10%-846.87%51.56%165.57%---

TGTX Forecast FAQ

Is TG Therapeutics stock a buy?

TG Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that TG Therapeutics is a favorable investment for most analysts.

What is TG Therapeutics's price target?

TG Therapeutics's price target, set by 13 Wall Street analysts, averages $49.5 over the next 12 months. The price target range spans from $39 at the low end to $60 at the high end, suggesting a potential 83.74% change from the previous closing price of $26.94.

How does TG Therapeutics stock forecast compare to its benchmarks?

TG Therapeutics's stock forecast shows a 83.74% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for TG Therapeutics over the past three months?

  • March 2026: 11.11% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.
  • February 2026: 11.11% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.
  • January 2026: 11.11% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.

What is TG Therapeutics’s EPS forecast?

TG Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $1.78, marking a -42.58% decrease from the reported $3.1 in 2025. Estimates for the following years are $2.86 in 2027, and $3.71 in 2028.

What is TG Therapeutics’s revenue forecast?

TG Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $748.29M, reflecting a 21.42% increase from the reported $616.29M in 2025. The forecast for 2027 is $997.2M, and $1.26B for 2028.

What is TG Therapeutics’s net income forecast?

TG Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $273.41M, representing a -38.86% decrease from the reported $447.18M in 2025. Projections indicate $448.46M in 2027, and $550.22M in 2028.